KINNATE BIOPHARMA INC(NASDAQ:KNTE) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to KNTE. KNTE was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KNTE as it has an excellent financial health rating, but there are worries on the profitability. KNTE is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year KNTE has reported negative net income.

In the past year KNTE has reported a negative cash flow from operations.

KNTE had negative earnings in each of the past 5 years.

In the past 5 years KNTE always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of KNTE (-64.89%) is worse than 62.35% of its industry peers.

The Return On Equity of KNTE (-70.70%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-64.89%
ROE	-70.7%
ROIC	N/A

ROA(3y)-43.69%

ROA(5y)-30.56%

ROE(3y)-50.27%

ROE(5y)-34.61%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

KNTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, KNTE has more shares outstanding

The number of shares outstanding for KNTE has been increased compared to 5 years ago.

KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 1.00, we must say that KNTE is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 1.00, KNTE is in the better half of the industry, outperforming 64.57% of the companies in the same industry.

KNTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

KNTE has a Current Ratio of 13.19. This indicates that KNTE is financially healthy and has no problem in meeting its short term obligations.

KNTE's Current ratio of 13.19 is amongst the best of the industry. KNTE outperforms 86.88% of its industry peers.

A Quick Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 13.19, KNTE belongs to the best of the industry, outperforming 87.05% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	13.19
Quick Ratio	13.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.68% over the past year.

EPS 1Y (TTM)8.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%50%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KNTE will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y47.95%

EPS Next 2Y28.83%

EPS Next 3Y13.35%

EPS Next 5Y13.7%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KNTE. In the last year negative earnings were reported.

Also next year KNTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as KNTE's earnings are expected to grow with 13.35% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.83%

EPS Next 3Y13.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KNTE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KINNATE BIOPHARMA INC

NASDAQ:KNTE (4/2/2024, 8:25:40 PM)

After market: 2.65 0 (0%)

2.65

-0.01 (-0.38%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-28 2024-03-28/amc

Earnings (Next)05-09 2024-05-09/amc

Inst Owners0.91%

Inst Owner Change0%

Ins Owners6.99%

Ins Owner Change0%

Market Cap125.00M

Analysts78

Price Target2.41 (-9.06%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)11.27%

Min EPS beat(2)5.59%

Max EPS beat(2)16.95%

EPS beat(4)4

Avg EPS beat(4)8.9%

Min EPS beat(4)1.96%

Max EPS beat(4)16.95%

EPS beat(8)7

Avg EPS beat(8)3.8%

EPS beat(12)7

Avg EPS beat(12)0.57%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)13.35%

PT rev (3m)-12.47%

EPS NQ rev (1m)1.14%

EPS NQ rev (3m)5.3%

EPS NY rev (1m)0%

EPS NY rev (3m)9.55%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.78
P/tB	0.78
EV/EBITDA	N/A

EPS(TTM)-2.42

EYN/A

EPS(NY)-1.26

Fwd EYN/A

FCF(TTM)-2.12

FCFYN/A

OCF(TTM)-2.12

OCFYN/A

SpS0

BVpS3.38

TBVpS3.38

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-64.89%
ROE	-70.7%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-43.69%

ROA(5y)-30.56%

ROE(3y)-50.27%

ROE(5y)-34.61%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	13.19
Quick Ratio	13.19
Altman-Z	1

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)365%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)8.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%50%

EPS Next Y47.95%

EPS Next 2Y28.83%

EPS Next 3Y13.35%

EPS Next 5Y13.7%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-0.42%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year43.09%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-9.04%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-12.37%

OCF growth 3YN/A

OCF growth 5YN/A

KINNATE BIOPHARMA INC (KNTE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens